Effects of chimeric somatostatin-dopamine molecules on human peripheral blood lymphocytes activation.
BIM 23A761, selective for somatostatin receptors subtypes 2, 5 and the dopamine receptor subtype 2, and BIM 23A757 with affinity for SSTR2 and DAR2 were studied on human PBL proliferation and activation. BIM 23A761 was significantly more potent than specific SSTR and DAR2 agonists in suppressing lymphocyte proliferation induced by mitogen or alloantigen, while BIM 23A757 was more potent than specific SSTR2 and DAR2 agonists in suppressing antigen induced proliferation only. Both molecules displayed enhanced potency in suppressing IFNgamma and IL-6 secretion compared with the SSTR and DAR2 analogs, while only BIM 23A761 was able to inhibit IL-2 secretion and its effect is more potent than the control analogs. Furthermore BIM 23A761 inhibit cell progression into the S phase and then into the G2/M, while BIM 23A757 inhibited bromodeoxyuridine incorporation only during the S phase. Both chimeric molecules resulted significantly more effective than the respective controls.
Casnici
C
C
Department of Pharmacology, School of Medicine, University of Milan, Italy.
Lattuada
D
D
Crotta
K
K
Mastrotto
C
C
Franco
P
P
Culler
M D
MD
Marelli
O
O
D000328:Adult; D049109:Cell Proliferation / Q000187:drug effects; D018491:Dopamine Agonists / Q000494:pharmacology*; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects*; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000737:chemistry; D017448:Receptors, Dopamine D2 / Q000819:agonists; D017481:Receptors, Somatostatin / Q000819:agonists / Q000737:chemistry; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D013004:Somatostatin / Q000819:agonists / Q000031:analogs & derivatives*
C470245:BIM 23023; C423390:BIM-23244; D018491:Dopamine Agonists; D010456:Peptides, Cyclic; D017448:Receptors, Dopamine D2; D017481:Receptors, Somatostatin; D011993:Recombinant Fusion Proteins; D013004:Somatostatin